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Abstract 
We discovered secular trend bias in a drug 
effectiveness study for a recently approved drug. 
We compared treatment outcomes between 
patients who received the newly approved drug 
and patients exposed to the standard treatment. 
All patients diagnosed after the new drug's 
approval date were considered.  We built a 
machine learning causal inference model to 
determine patient subpopulations likely to 
respond better to the newly approved drug. After 
identifying the presence of secular trend bias in 
our data, we attempted to adjust for the bias in two 
different ways. First, we matched patients on 
number of days from the new drug’s approval date 
that the patient's treatment (new or standard) 
began. Second, we included a covariate in the 
model for number of days between the date of 
approval of the new drug and the treatment (new 
or standard) start date. Neither approach 
completely mitigated the bias. Residual bias we 
attribute to differences in patient disease severity 
or other unmeasured patient characteristics. Had 
we not identified the secular trend bias in our data, 
the causal inference model would have been 
interpreted without consideration for this 
underlying bias. Being aware of, testing for, and 
handling potential bias in the data is essential to 
diminish the uncertainty in AI modeling. 
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1. INTRODUCTION 
Patient medical data is expanding in scope and depth. 
Advances in mining unstructured text will eventually 
surface the estimated 80% of patient data currently 
unavailable in clinical notes. [1] In addition, ~omics data is 
expected to become readily available. The application of 
AI approaches to medical data is expected to result in 
significant advances in medicine. [2,3,4] However, there is 
distrust of AI in medicine and uncertainty about the results 
and insights generated with machine learning algorithms. 
[5] Data scientists working in medicine need to be 
particularly vigilant about bias and confounding since 
patient level decisions could eventually be influenced by 
model results. [6] In this paper, we expose an important 
bias in the use of prescription fill data. And demonstrate 
that consideration of drug adoption patterns in medical 
practice need to be assessed when comparing treatment 
effects in patient data.  
2. METHODS 
In a drug effectiveness study using real world data, we 
studied a drug which was recently approved for first line 
treatment and was the first drug in a new drug class. In our 
study design, we included patients who either took the 
newly approved drug (Drug A) or the standard treatment 
(Drug B). All the patients in the cohort were diagnosed at 
the time of or after Drug A's approval. Patients were given 
either Drug A or Drug B.  The observation started at the 
beginning of treatment and ended at either death of the 
patient, disenrollment from the health plan, or end of the 
study, which ever came first.  Outcome of interest was lack 
of treatment effectiveness (LTE) as defined by clinical 
experts.  
We tested two approaches to control for the bias: matching 
patients on how many days from the new drug's approval 
the patient’s treatment began and adding a covariate to the 
 model for the number of days from the new drug's approval 
and treatment initiation. A third approach, that was not 
feasible in our data, would be to compare patients only after 
prescribing behavior suggested full clinical adoption of the 
new drug. We also assessed the prescribing patterns in a 
selection of other newly approved drugs to determine if our 
observation was unique.  
2.1 MATCHING PATIENTS 
Both treatment groups included patients who initiated 
treatment after the date of approval of Drug A. The ratio of 
patients taking Drug A versus Drug B changed over time. 
We matched patients receiving Drug A with patients 
receiving Drug B on date of treatment initiation ± 30 days 
using a 1 to 3 ratio (new to standard drug). When more than 
3 matches were available we randomly selected the 
matches.  
2.2 USING A TEMPORAL FEATURE 
We included a model covariate in our causal inference 
models for the number of days from Drug A's approval and 
when treatment initiation began. We also built machine 
learning models and calculated the feature importance for 
days between drug approval date and date when the patient 
started treatment. 
2.3 STARTING THE OBSERVATION PERIOD 
AFTER THE END OF SECULAR TREND  
Another way to overcome secular trend bias is to start the 
study's observation period after clinical adoption has 
occurred. In our study, the recency of the drug's approval 
did not allow a long enough follow-up period to construct 
causal inference models on treatment effectiveness this 
way. However, in theory, this approach would control for 
the adoption effect as well as the potential that treatment 
assignment is based on disease severity.  
2.4 ASSESSING SECULAR TRENDS IN OTHER 
NEWLY APPROVED DRUGS  
To determine if our observations of secular trend bias in 
Drug A were unique, we selected three drugs approved in 
similar years to Drug A. Using the same dataset, we looked 
at all prescriptions filled from the drug's approval date. 
Then we assessed the patterns that emerged for each drug. 
3. RESULTS 
A total of 939 patients were prescribed Drug A and 1833 
patients were prescribed Drug B. All patients were the 
same sex. Race/ethnicity was not available in the data set. 
The mean number of observation days was µ=366 
(sd=230.6) for patients taking Drug A and µ=422 
(sd=249.36) for patients taking Drug B. The t-test for 
difference in means was 2.97, p-value 0.0029.   
Figures 1 and 2 represent the number of patients receiving 
each drug over time with trend lines superimposed.  
 
 
 
Figure 2: Distribution of patients who started Drug B. X-
axis shows days from Drug A's approval that treatment was 
initiated and Y-axis shows number of patients initiating 
treatment on that day. Orange colored line is to show the 
predominant pattern of Drug B prescribing. 
Figure 3 shows the characteristics that separate responders 
to Drug A vs. Drug B in our population using the Ozery-
Flato method. [7] When separating the population into 
responders for Drug A compared to responders to Drug B, 
days from Drug A's approval remains influential in 
defining patients’ treatment response. Those who 
responded better to Drug A were assigned that treatment 
well over a year after the drug’s approval. While patients 
who did better on Drug B were more likely to receive the 
standard treatment in the 6-8 months following the new 
treatment's availability.  
 
 
Figure 1: Distribution of patients who started Drug A. 
X-axis shows days from the approval of Drug A that 
treatment was initiated and Y-axis shows number of 
patients initiating treatment on that day. Orange line 
shows the predominant pattern of Drug A prescribing. 
 Results of our causal inference model show the continued 
influence of the bias even time from approval is included 
in the model as a covariate.  
 
Figure 3: Influence of effect modifiers in causal inference 
model 
Figures 4-6 show the prescribing patterns observed in the 
24 months following approval for three drugs approved in 
the same time period as Drug A for various conditions. 
These include Acyclovir (antiviral, BioAlliance Pharma, 
April 2013), Dolutegravir (anti-retroviral, ViiV 
Healthcare, August 2013), and Lorcaserin (weight 
management, Arena Pharmaceuticals, June 2012). There is 
considerable variation in clinical adoption of these new 
drugs.  
 
Figure 4: Distribution of patients who started Acyclovir (in 
first 24 months of its approval) 
 
Figure 5: Distribution of patients who started Dolutegravir 
(in first 24 months of its approval) 
 
Figure 6: Distribution of patients who started Locaserin 
(in first 24 months of its approval) 
 
4. DISCUSSION 
In our study, we observed a significant difference in the 
mean number of observation days for those prescribed 
newly approved Drug A versus the standard of treatment 
Drug B. The average number of person-days on Drug A vs. 
Drug B was skewed and led to discovering a prescriber bias 
in treatment assignment. We reasoned that since the drug 
represented a new class of therapy not previously 
experienced by the doctors there was an adopter effect. 
Martin, et al discuss change in drug prescription pattern 
between clinical trials and post marketing. [8] Menzel, et 
al studied how social relations in a community of doctors 
can influence adoption of new treatments. [9] In addition, 
we believe the treatment was more likely in the beginning 
to be assigned to more severe patients. Stern, et al suggest 
that adoption of a new prescription drug also depends on 
 prescription pattern of the prior drug category [10]. Many 
have [11,12] discussed evaluation of drugs in the real world 
and the potential biases. It is important that bias be assessed 
in the data before machine learning techniques are applied 
so that erroneous conclusions are not made. We tested 
multiple methods to control for the observed secular trend 
bias in our study, but residual bias remained such that 
machine learning could not be applied in our analysis.  
As medical data grows in scope and depth, machine 
learning will be able to mine much needed insight from the 
data to positively impact clinical practice and patient 
health. However, data scientists need to be aware that 
potential heretofore unknown bias may lurk in the data. 
This bias needs to be identified and addressed in machine 
learning to minimize the uncertainty of AI. Being able to 
name and address the bias will also strengthen 
practitioners' adoption of the new knowledge approach of 
AI.  
Our data show that prescriber patterns are influenced by 
many factors that when possible need to be accounted in 
models of treatment effect. We found that Drug A was not 
the only drug affected by secular trend bias in prescribing 
patterns. This could be due to higher cost of the newer drug, 
lack of physician experience with the drug especially when 
it represents a new drug class, or physician adoption 
readiness.  
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